Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34198671/
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. The high mortality is very often a consequence of its late diagnosis when the cancer is already locally...
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.
Mayo Clinic study suggests patients with lung cancer be screened for MET oncogene
ROCHESTER, Minn. - Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy. Their findings...
Acquired Resistance to KRAS G12C Inhibition in Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34161704/
Diverse genomic and histologic mechanisms impart resistance to covalent KRAS G12C inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer. (Funded...
-
KRAS Oncogene Connect5yrKey Points • Via cell-based experiments and deep mutational scanning experiments, researchers performed genomic and histologic analysis to determine adagrasib-resistance patterns in 38 patients with KRAS G12C-mutated cancer. • In total, 17 of 38 Show More
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • Via cell-based experiments and deep mutational scanning experiments, researchers performed genomic and histologic analysis to determine adagrasib-resistance patterns in 38 patients with KRAS G12C-mutated cancer. This study Show More
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34119437/
1 Department of Internal Medicine, AdventHealth Orlando, Orlando, FL. 2 Research Institute, AdventHealth Orlando, Orlando, FL. 3 Thoracic Oncology Program, AdventHealth Cancer Institute, Orlando, FL. 4 Department of Pathology and...
Nonclinical Safety Profile of Sotorasib, a KRAS G12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34137282/
Sotorasib is a first-in-class KRAS G12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. A comprehensive nonclinical safety assessment package, including secondary/safety pharmacology...